Get the Weekly Intelligence Brief — top committee picks every Sunday.
DGX · NYSE · STOCK

Quest Diagnostics (DGX) Stock Analysis

Healthcare Updated August 24, 2026
$243.98
52W $171.18 – $245.68
61/100
$26.97B
25.6
0.55
AI Committee Verdict
Buy
61/100
Conviction: Moderate · 60% agreement · 5 analysts
-23.8%
Moderate

Is DGX Bullish or Bearish?

Bullish. Innellis AI committee rates Quest Diagnostics (DGX) Buy with a composite score of 61/100 , based on 5 analysts with 60% agreement. Last updated August 24, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +14.15 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -5.85 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Positive signals support the current rating — 5 consecutive earnings beats -- consistent execution. The committee sees sufficient evidence to maintain the constructive view.

Bull & Bear Case

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • RSI at 79 is in overbought territory — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
  • Weekly RSI at 78 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 24, 2026
Overall Committee Score
61/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 31%
of 192 Healthcare peers
Value Analyst neutral
58 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
Growth Analyst bullish
68 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst neutral
54 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 79 is in overbought territory
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
60 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 60.9 to 60.9.

Comparing 2026-08-23 to 2026-08-24 (1 day apart).

Technical Analysis

RSI (14)
79.5
Overbought
MACD Histogram
-0.282
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
1.11
Above Upper Band
Price vs Moving Averages
EMA 9
$239.09 Above
EMA 21
$233.81 Above
EMA 50
$222.72 Above
EMA 200
$201.53 Above

Fundamental Analysis

Valuation
58
Growth
87
Profitability
52
Financial Health
74
Cash Flow
70
Valuation
P/E Ratio 25.6×
P/B Ratio 3.58×
PEG Ratio 2.03
Dividend Yield 1.36%
52W High $245.68
52W Low $171.18
Quality & Growth
ROE 1383.5%
ROA 611.4%
Gross Margin 3314.9%
Operating Margin 1414.4%
Revenue Growth YoY
Debt / Equity 0.85
AI Fundamental Assessment
P/E ratio of 25.6 (moderate relative to a 15-40x range); Price-to-book of 3.6x; PEG ratio of 2.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 13.8%; Return on assets of 6.1%; Net margin of 9.2%; Gross margin of 33.1%; Current ratio of 1.59 (healthy short-term liquidity); Debt-to-equity of 0.85; Free cash flow per share is positive (11.09); Most recent quarter beat estimates by 9.3%; 5 consecutive earnings beats; EPS growth accelerating (+3.3% -> +24.8% QoQ); Average YoY EPS growth of 19.1%; Analyst estimates rising over recent quarters
Get the Full DGX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime